EU & US BASED
SphingoTec is headquartered near Berlin, Germany while its wholly owned subsidiary Nexus Dx is based in San Diego, CA, USA.
IP PROTECTION
All of SphingoTec's biomarkers are globally patent protected
COMMERCIAL PLATFORM
Diagnostic assays for SphingoTec‘s biomarkers are available on its proprietary fully developed and commercialized POC platform Nexus IB10
CLINICAL DEVELOPMENT
SphingoTec’s biomarkers are broadly validated and published in peer-reviewed journals
DIAGNOSTIC SOLUTIONS
In collaboration with an international network of key opinion leaders, SphingoTec develops solutions for fighting mortality in critical care conditions
KNOW-HOW
SphingoTec’s management builds on an extraordinary track-record in R&D and commercialization of novel diagnostic solutions
Innovative acute care biomarkers
Following a deep understanding of disease biology, SphingoTec develops novel biomarkers addressing diagnostically underserved critical care conditions such sepsis, acute heart failure, acute kidney injury, and cardiogenic shock.
Point-of-care testing with Nexus IB10 Analyzer
The CE-IVD marked Nexus IB10 platform is a fully automated rapid immunoassay point-of-care instrument. With a hands-on-time of less than 3 minutes the easy-to-use system provides in only 20 minutes test results for biomarkers that are crucial in the management of critical care patients.
Acute Care Pathways
Sepsis
Diagnostic tools in Sepsis
Recent research has identified new molecules that are informative and help clinicians understand the etiology of the patient’s clinical symptoms, paving the way for personalized medicine in the field of sepsis.
COVID-19
Biomarkers and the management of COVID-19 patients
The global COVID-19 pandemic has challenged health systems world-wide, with about 5% of patients requiring admission to intensive care units (ICU). Read more on the importance of novel and established biomarker assays in the management of critically ill COVID-19 patients.
Latest News
Events & Expos
09:00 - 09:00
09:00 - 13:18
09:00 - 08:30